



NEWS RELEASE

Moderna Tops BioSpace's 2022 Best Places to Work Ranking in Large Employer Category

11/17/2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 17, 2021-- **Moderna, Inc.**, (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it was ranked the number one employer in BioSpace's **2022 Best Places to Work in Biopharma** report.

"We are honored to be recognized by BioSpace for career growth and development, leadership, culture, benefits, and innovation and drug pipeline. This is another recognition our employees' dedication and relentless pursuit of our mission," said Stéphane Bancel, Chief Executive Officer of Moderna. "Since our founding, we have been committed to bringing a new class of mRNA medicines to people around the world. Being recognized as a great place to work is meaningful when looking at where we began as a company, and as we grow, we are focused on maintaining the values and mindsets we have had since the beginning."

Over the past year, Moderna's COVID-19 response efforts created hundreds of jobs, increasing its employee numbers from 800 in 2019 to more than 2,400 employees as of September 2021. The Company is making several investments to support employees as the organization continues to scale, and recently **announced** an expansion of the Moderna Technology Center in Norwood, including more than doubling of space to transform the facility from a production and lab space to an industrial technology center.

Additionally, the Company will invest in a new Moderna Science Center, a purpose-built space to support the Company's next chapter of discovery. Beyond expanding the physical space where employees can innovate, the Company remains committed to upholding its founding values, maintaining an inclusive culture and investing in training and development programs to support employees through another exciting year for Moderna.



Conducted in September 2021, research for the BioSpace ranking included responses from over 2,000 life sciences professionals. Respondents were asked to identify their top three most desirable biopharma companies, segmented by large (defined as more than 1,000 employees) and small (fewer than 1,000 employees) companies. Respondents were also asked to rate the importance of 10 attributes (i.e., benefits, etc.) when thinking of top employers. Career growth and development were rated most highly, followed by leadership and pay. To view the complete lists of 2022 Best Places to Work, [click here](#).

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company's investments in its workforce, and investments in the expansion of the Moderna Technology center and its Moderna Science Center. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements

contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.

View source version on **businesswire.com**: <https://www.businesswire.com/news/home/20211117005889/en/>

Moderna Contacts

Media:

Colleen Hussey

Director, Corporate Communications

617-335-1374

Colleen.Hussey@modernatx.com

Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834

Lavina.Talukdar@modernatx.com

Source: Moderna, Inc.